Impact of MTHFR gene C677T polymorphism on Bcl-2 gene methylation and protein expression in colorectal cancer

References

• Qian ZR, Sano T, Yoshimoto K, Yoshimoto K, Asa SL, Yamada S, Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 2007;20:1269–77.
   PubMed Web of Science ®Google Scholar
• Goldstein M, Meller I, Orr-Urtreger A. FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG island and abnormal expression of the AKT1, NOG, and BMP4 gene. Gene Chromosome Cancer 2007;46:1028–38.
   PubMedGoogle Scholar
• Calvisi DF, Simile MM, Ladu S. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int J Cancer 2007;121:2410–20.
   PubMedGoogle Scholar
• Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606–11.
   PubMed Web of Science ®Google Scholar
• Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994;7:195–200.
   PubMed Web of Science ®Google Scholar
• Brockton NT. Localized depletion: the key to colorectal cancer risk mediated by MTHFR genotype and folate? Cancer Causes Control 2006;17:1005–16.
   PubMed Web of Science ®Google Scholar
• Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004;159:423–43.
   PubMed Web of Science ®Google Scholar
• Clarizia AD, Bastos-Rodrigues L, Pena HB, Anacleto C, Rossi B, Soares FA, Relationship of the methylenetetrahydrofolate reductase C677T polymorphism with microsatellite instability and promoter hypermethylation in sporadic colorectal cancer. Genet Mol Res 2006;5:315–22.
   PubMedGoogle Scholar
• Siraj AK, Ibrahim M, Al-Rasheed M, Bu R, Bavi P, Jehan Z, Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Ann Hematol 2007;86:887–95.
   PubMedGoogle Scholar
• Tao MH, Shields PG, Nie J, Marian C, Ambrosone CB, McCann SE, DNA promoter methylation in breast tumors: no association with genetic polymorphisms in MTHFR and MTR. Cancer Epidemiol Biomarkers Prev 2009;18:998–1002.
   Google Scholar
• Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005;96:173–80.
   PubMed Web of Science ®Google Scholar
• Weng YR, Sun DF, Fang JY, Gu WQ, Zhu HY. Folate levels in mucosal tissue but not methylenetetrahydrofolate reductase polymorphisms are associated with gastric carcinogenesis. World J Gastroenterol 2006;12:7591–7.
   PubMedGoogle Scholar
• Vaux D, Cory S, Adams J. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–2.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1–6.
   PubMed Web of Science ®Google Scholar
• Dueñas-González A, Abad-Hernández MM, Cruz-Hernández JJ, González-Sarmiento R. Analysis of bcl-2 in sporadic breast carcinoma. Cancer 1997;80:2100–8.
   PubMedGoogle Scholar
• Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
   Google Scholar
• Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821–6.
   PubMed Web of Science ®Google Scholar
• Paredes J, Albergaria A, Oliveira JT, Jerónimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005;11:5869–77.
   PubMed Web of Science ®Google Scholar
• Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K, Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 2003;23:1663–70.
   PubMed Web of Science ®Google Scholar
• Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–13.
   PubMed Web of Science ®Google Scholar
• Petrişor O, Giuşcă SE, Sajin M, Dobrescu G, Căruntu ID. Ki-67, p53 and bcl-2 analysis in colonic versus rectal adenocarcinoma. Rom J Morphol Embryol 2008;49:163–71.
   PubMedGoogle Scholar
• Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 2007;96:1409–18.
   PubMed Web of Science ®Google Scholar
• Mignotte B, Vayssiere JL. Mitochondria and apoptosis. Eur J Biochem 1998;252:1–15.
   PubMedGoogle Scholar
• McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18). Nature 1991;349:254–6.
   PubMed Web of Science ®Google Scholar
• Mikami T, Yanagisawa N, Baba H, Koike M, Okayasu I. Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer 1999;85:318–25.
   PubMed Web of Science ®Google Scholar
• Lima MA, Ferreira MV, Barros MA. Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas. Diagn Mol Pathol 2008;17:82–9.
   PubMedGoogle Scholar
• Sjöström-Mattson J, Von Boguslawski K, Bengtsson NO, Mjaaland I, Salmenkivi K, Blomqvist C. The expression of p53, bcl-2, bax, fas and fasL in the primary tumor and lymph node metastases of breast cancer. Acta Oncol 2009;48:137–43.
   PubMedGoogle Scholar
• Hanaoka T, Nakayama J, Haniuda M, Sato TA. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers. Int J Clin Oncol 2002;7:152–8.
   PubMedGoogle Scholar
• Anderson NS, Turner L, Livingston S, Chen R, Nicosia SV, Kruk PA. Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation. J Ovarian Res 2009;2:16.
   PubMed Web of Science ®Google Scholar
• Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res 2009;7:1487–96.
   PubMed Web of Science ®Google Scholar
• Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein–Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumor suppressor gene Bim. PloS Pathog 2009;5:e1000492.
   Google Scholar
• Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059–70.
   PubMed Web of Science ®Google Scholar
• Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993;3:226–31.
   PubMed Web of Science ®Google Scholar
• Das PM, Singal R. DNA methylation and Cancer. J Clin Oncol 2004;22:4632–42.
   PubMed Web of Science ®Google Scholar
• Babidge WJ, Butler LM, Burton MA, Cowled PA. Methylation of CpG sites in exon 2 of the bcl-2 gene occurs in colorectal carcinoma. Anticancer Res 2001;21:2809–14.
   PubMedGoogle Scholar
• Malentacchi F, Forni G, Vinci S, Orlando C. Quantitative evaluation of DNA methylation by optimization of a differential-high resolution melt analysis protocol. Nucleic Acids Res 2009;37:e86.
   PubMedGoogle Scholar
• Tao MH, Shields PG, Nie J, Marian C, Ambrosone CB, McCann SE, DNA promoter methylation in breast tumors: no association with genetic polymorphisms in MTHFR and MTR. Cancer Epidemiol Biomarkers Prev 2009;18:998–1002.
   Google Scholar
• Sohn KJ, Jang H, Campan M, Weisenberger DJ, Dickhout J, Wang YC, The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int J Cancer 2009;124:1999–2005.
   PubMed Web of Science ®Google Scholar
• Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001;61:3272–5.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Matsuo K, Hirose K, Hiraki A, Kawase T, Watanabe M, One-carbon metabolism related gene polymorphisms and risk of breast cancer. Carcinogenesis 2008;29:356–62.
   PubMed Web of Science ®Google Scholar
• Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862–4.
   PubMed Web of Science ®Google Scholar
• Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57(6):1098–102.
   PubMedGoogle Scholar
• Hekim N, Ergen A, Yaylim I, Yilmaz H, Zeybek U, Oztürk O, No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct 2007;25:115–17.
   PubMed Web of Science ®Google Scholar
• Park KS, Mok JW, Kim JC. The 677C > T mutation in 5,10-methylenetetrahydrofolate reductase and colorectal cancer risk. Genet Test 1999;3:233–6.
   PubMedGoogle Scholar
• Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813–20.
   PubMed Web of Science ®Google Scholar
• Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009;22:922–32.
   PubMed Web of Science ®Google Scholar
• Contu PC, Contu SS, Moreira LF. Bcl-2 expression in rectal cancer. Arq Gastroenterol 2006;43:284–7.
   PubMedGoogle Scholar
• Ismail HM, El-Baradie M, Moneer M, Khorshid O, Touny A. Clinico-pathological and prognostic significance of p53, Bcl-2 and her-2/neu protein markers in colorectal cancer using tissue microarray. J Egypt Natl Canc Inst 2007;19:3–14.
   PubMedGoogle Scholar
• Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T, Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. In Vivo 2007;21:113–18.
   PubMed Web of Science ®Google Scholar
• Sena P, Roncucci L, Marzona L, Mariani F, Maffei S, Manenti A, Altered expression of apoptosis biomarkers in human colorectal microadenomas. Cancer Epidemiol Biomarkers Prev 2010;19:351–7.
   PubMedGoogle Scholar
• Kim YI. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev 2004;13:511–19.
   PubMed Web of Science ®Google Scholar
• Mokarram P, Naghibalhossaini F, Saberi Firoozi M, Hosseini SV, Izadpanah A, Salahi H, Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. World J Gastroenterol 2008;14:3662–71.
   PubMed Web of Science ®Google Scholar